Hyperfine, Inc.
HYPR
Khan Siddiqui, M.D.
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Khan Siddiqui, M.D.
Hyperfine, Inc. reported in an 8-K filed October 3, 2023 that Khan Siddiqui, M.D. was terminated as Chief Medical Officer and Chief Strategy Officer, effective September 30, 2023.
“On September 27, 2023, Hyperfine, Inc. (the "Company") terminated Khan Siddiqui, M.D.'s part-time employment as the Company's Chief Medical Officer and Chief Strategy Officer, effective September 30, 2023 (the "Separation Date"), following which Dr. Siddiqui will continue to serve as a consultant of the Company.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Hyperfine, Inc. (HYPR)
SEC 8-K
2021-12-22–2023-09-30
Company network
Recorded roles and call appearances connecting this person to public companies.
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.